Currently, thrombolysis is offered to less than 1% of patients in low to middle income
countries (LMICs) where access to health care is often based on the financial capabilities of
the patient. There is therefore an urgent need for an effective but affordable alternative
thrombolytic agent. Streptokinase (SK) ($35) is much more economically feasible as opposed to
tissue plasminogen activator (tPA) ($2800). In this study, we propose a reevaluation of the
use of streptokinase (SK) in the treatment of acute ischemic stroke. We want to emphasize
that we will only consider this as a 'treatment option' if we are absolutely certain that IV
tissue plasminogen activator (tPA) will not be offered to the patient due to its high cost.
It is hypothesized that treatment with SK in appropriately selected patients will be
associated with a hemorrhagic transformation rate similar to that of tPA.